Physician

Adela Dina Mattiazzi, MD

According to 2025 Medicare claims, Adela Mattiazzi, MD (NPI: 1922200260) practices nephrology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is UNIVERSITY OF MIAMI (NPI: 1760434286; TIN: 592579938) and primary practice location at 33136-1005.

Mattiazzi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 239 traditional Medicare patients, billed 872 HCPCS/CPT codes, and received $69,158 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,924 prescription claims across 403 beneficiaries totaling $6,249,016 in drug costs, led by Privigen (Immun Glob G(Igg)/Pro/Iga 0-50). DME data shows 1,392 claims. Open Payments data shows 3 records totaling $53,652. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $108,866 to $69,158. In contrast, Part D prescription costs have risen steadily, from $3,002,761 to $6,249,016. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $15 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	398	1,442	$108,866
2016	485	1,930	$144,256
2017	454	1,413	$105,768
2018	451	1,643	$129,524
2019	497	1,944	$148,842
2020	446	1,869	$142,643
2021	407	1,143	$92,953
2022	333	1,132	$91,072
2023	270	869	$76,182
2024	239	872	$69,158

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	296	3,512	$3,002,761
2016	426	5,200	$4,754,797
2017	577	7,599	$5,362,480
2018	583	7,394	$4,318,642
2019	681	7,430	$5,578,915
2020	749	10,515	$6,872,443
2021	758	10,906	$8,441,042
2022	589	5,008	$6,674,325
2023	352	3,266	$5,600,775
2024	403	2,924	$6,249,016

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	343	1,459	$233,073
2016	627	2,692	$386,922
2017	1,190	5,609	$796,652
2018	1,275	7,198	$981,196
2019	1,038	5,832	$817,883
2020	1,017	5,643	$706,420
2021	1,170	7,173	$600,317
2022	786	3,714	$222,700
2023	389	1,783	$108,066
2024	346	1,392	$79,835

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	57	60	$137
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	75	81	$104
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	40	130	$99
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	121	391	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	40	42	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	121	3,297	$2,053,861
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	87	2,384	$1,709,611
Gammaked	Immune Globul G/Gly/Iga Avg 46	46	1,312	$1,045,959
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	35	980	$512,634
Procrit	Epoetin Alfa	30	850	$101,252

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7527	Everolimus, oral, 0.25 mg	N	N/R	23	$26,484
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	44	$21,855
J7518	Mycophenolic acid, oral, 180 mg	N	58	225	$13,581
J7507	Tacrolimus, immediate release, oral, 1 mg	N	79	329	$7,272
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	109	507	$6,217

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$154	CALLIDITAS THERAPEUTICS US INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$53,498	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adela Dina Mattiazzi, MD?

Tedicare shows public-source Medicare data for Adela Dina Mattiazzi, MD (NPI 1922200260), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adela Dina Mattiazzi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adela Dina Mattiazzi, MD?

Adela Dina Mattiazzi, MD is linked to UNIVERSITY OF MIAMI (billing NPI 1760434286) in the available physician profile data.

Does Adela Dina Mattiazzi, MD have Open Payments data?

Adela Dina Mattiazzi, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.